In 2002 Diasorin acquired BYC Sangtec and the rights to the Liaison platform. The commercial expansion led to the opening of new branches in Mexico, Israel, and China. The Liaison portfolio was enriched with products for new and clinical specialty areas. In the same year, tests previously developed with ELISA technology were converted to the most recent and automated CLIA.
On July 19, 2007, the Diasorin title debuted at Borsa Italiana Stock Exchange.
In 2014 the company obtained the approval of hepatitis and retrovirus tests in China; in the same year, Diasorin launched new tests to detect leukemias. Diasorin Group signed an agreement in 2015 with Beckman Coulter for the commercialization in China of Diasorin hepatitis and HIV tests. In 2016, Diasorin and Beckman Coulter signed an additional partnership, with the aim to provide customers in the U.S. the same hepatitis and HIV tests. The two companies are working together to submit the products to the Food and Drug administration (FDA) for approval and commercialization in the U.S. In this year, the group acquired of Focus Diagnostics’ business unit, enabling it to expand its activities in molecular diagnostics.
In 2017, a partnership with Qiagen offered an automated solution for detection of tuberculosis with QuantiFERON-TB Gold Plus available on the Liaison analyzers. That was also the year of the Siemens Healthineers ELISA business acquisition.
Read the full text
In October 2018 the Saluggia branch began a partnership with Meridian for the distribution of a Helicobacter pylori detection test in the United States and United Kingdom. The companies have put in place a framework under which they may work together on the development of new tests and products.
In 2019 the commercial launch of Liaison XS approval of latent tuberculosis test in the United States.
In 2020 Diasorin signed an exclusive license agreement with TTP for the automation of molecular diagnostic tests on a Point-of-Care platform.
In September 2020 Diasorin and MeMed started a strategic partnership for the development and commercialization of a diagnostic solution based on the patients' immune response that can differentiate between bacterial and viral infections.
In April 2021, in partnership with QIAGEN, Diasorin launched in countries accepting the CE Mark the LIAISON LymeDetect test for the early diagnosis of Lyme Borreliosis, based on the QuantiFERON technology.
On 14 July 2021 Diasorin announced the completion of the acquisition of Luminex Corporation.
.svg){kind=link}